|
|
For additional information or questions about this module, please contact:
Department of Continuing Medical Education
City of Hope
1500 East Duarte Road
Building 94
Duarte, CA 91010
Email: cme@coh.org
Fax: 626-301-8939
Phone: 626-256-4673, ext. 65622
|
|
|
You must have the media specifications below in order to have a pleasant and hassle-free viewing experience.
From YouTube:
To watch YouTube videos, you will need to have Flash installed. Download Adobe Flash
If you are trying to watch from a mobile device, YouTube has iOS (iPhone) and Android apps available to download for your mobile device. Click here to find links to currently available mobile apps.
Visit the YouTube help page for additional assistance.
|
|
|
|
Release date: November 22, 2011
Estimated time to complete activity: 1.25 hours
To obtain CME credit:
Complete the evaluation form
Submit to CME department via fax, 626-301-8939, email, cme@coh.org, or standard mail,
1500 E. Duarte Rd., Building 94, Duarte, CA 91010
Questions: 626-256-4673, ext. 65622
Additional Resources:
Reading List
|
|
|
In the US, renal cell cancer (RCC) accounts for about 3% of all adult cancers. NCI data indicate that an estimated 58,000 new cases of kidney cancer were diagnosed in 2010, and approximately 13,000 Americans died of the disease. Surgery to remove the affected kidney is the most common initial treatment for all stages of kidney cancer. However, regionally advanced or metastatic cases account for approximately half of all new cases. Historically survival rates for these patient populations have been about 20%. This poor prognosis combined with modest efficacy and high toxicity associated with currently available therapies for RCC has necessitated and resulted in the development of newer targeted therapies in order to improve outcome in these patient groups. This activity has been designed to provide the health care professional with the most current clinical and investigative data pertaining to new less invasive surgical techniques for the primary management of RCC and the expanding role of emerging multi-targeted therapies for patients with regionally advanced or metastatic RCC.
|
|
|
Upon successful completion of this activity, the learner should be better able to:
-
Review "traditional" and less invasive surgical techniques for the management of kidney cancer
-
Examine how new multi-targeted therapies beneficially impact the management of metastatic kidney cancer
-
Discuss current therapeutic approaches to the treatment of metastatic kidney cancer
-
Describe the multidisciplinary treatment paradigm for the treatment of kidney cancer
|
|
|
This activity has been designed to meet the needs of medical oncologists, urologists, internists and allied health care providers who treat patients with kideny cancer.
|
|
|
The City of Hope is accredited by the Accreditation Council for Continuing Medical education to provide continuing medical education for physicians.
|
|
|
City of Hope designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following may apply CME Category 1 credit for license renewal:
Registered Nurses: Nurses may report up to 1.25 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). CME may be noted on the license renewal application in lieu of a BRN provider number.
Physician’s Assistants: The National Commission on certification of Physicians Assistants states that AMA accredited Category 1 courses are acceptable fro CME requirements for recertification.
To receive CME credit, it is necessary to complete the post test & evaluation form. For more information, please click here.
|
|
|
City of Hope has implemented policies and procedures to be in strict compliance with current ACCME Standards of Commercial Support requiring disclosure and resolution conflicts of interest.
As part of these new commercial guidelines, we are required to disclose if Faculty , Presenters, Authors, Planners, CME Committee Members, Course Directors and / or Moderators have any real or apparent vested commercial interest(s) in both those companies whose products may be discussed/described during the course of the activity and in those companies who may be acting as commercial supporters of the activity.
Learn more >>
This activity may contain discussion of published and/or investigational uses of agents that are not approved/indicated by the US Food and Drug Administration (FDA).
Learn more >>
|
|
|
|
City of Hope collect the information provided by the user. The information is used to provide CME certification and to notify users of up coming programs and education information that may be of interest to our users. The information is not shared with others for commercial purposes, unless the user has granted prior permission.
|
|
|
All rights reserved: for personal use only. No part of this presentation may be translated, reproduced or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.
|
|
|
|
|
|  |
|
| Advanced Search Options |
| News & Publications Search |
 |
|
|
|
There are no fees for participating and receiving CME credit for this activity.
This activity is valid for CME credit from Nov 22, 2011 to Nov 22, 2012.
During this period participants must:
- Read the learning objectives and faculty disclosures
- Study the educational material
- Complete the post-test and evaluation form
Estimated time frame for completion of this activity, including the time to complete the post-test and evaluation form, is 1.25 hr(s).
|
|
|
The internet was selected as the instructional format to accommodate the learning preferences of a significant portion of the target audience.
|
|
|
